IPO
IPO filing, visualized

Lycia Therapeutics, Inc.

LYCA · Nasdaq424B4 · Oct 23, 2026Priced Oct 22, 2026

Priced Oct 22, 2026 · range was $16–$18 · latest SEC filing Nov 4, 2026.

Pinch-zoom for details.

The offering

Final price
$18.00
per share, from the final prospectus
Shares offered
17.6M
+2.65M over-allotment option
Raise at the final price
$318M
17,640,000 × $18, before fees

What the company does

Clinical-stage biotech developing drugs that degrade disease-causing proteins outside cells (its LYTAC platform), starting with autoimmune, inflammatory and allergic diseases.

Things to weigh

  • The filing's financial tables couldn't be read reliably, so none are shown here.

Risks

  1. We have a limited operating history, have not completed any clinical trials and have no products approved for commercial sale…
  2. We have incurred significant operating losses since our inception and have not generated any revenue from product sales
  3. Even if this offering is successful, we will require substantial additional capital to finance our operations and achieve our goals

The filing's own risk-factor headings, shortened.

Strategy

The filing doesn't set out its strategy in a list we could read.

Source: Lycia Therapeutics, Inc.'s Form 424B4, filed with the SEC on Oct 23, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.